ADAM17 and cancer: Our work identifies that intervention at the level of iTAP/Frmd8 may be beneficial to target the inflammatory features of ADAM17 associated with iRhom2, and shows new insights of the iTAP/Frmd8-mediated sheddase complex on cancer growth regulation.